No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
605177 Zhejiang East-Asia Pharmaceutical
- 20.17
- +0.26+1.31%
Market Closed Dec 20 15:00 CST
2.31BMarket Cap28.61P/E (TTM)
20.23High19.75Low19.75KlotVolume19.81Open19.91Pre Close39.53MTurnover1.72%Turnover Ratio19.08P/E (Static)114.75MShares29.1352wk High1.21P/B2.31BFloat Cap14.6452wk Low21.90Limit Up114.75MShs Float56.09Historical High17.92Limit Down2.41%Amplitude14.64Historical Low0.33Dividend TTM20.02Avg Price7.97KlotAsk1.62%Div YieldTTM100Lot Size11.17KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Zhejiang East-Asia Pharmaceutical (605177.SH) granted 2.1701 million shares of restricted stocks at a grant price of 9.47 yuan per share.
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that the fourth director's meeting will be held on December 6, 2024...
Zhejiang East Asia Pharmaceutical Gets South Korea Nod for Dyspepsia Drug
Express News | Zhejiang East-Asia Pharmaceutical: Mosapride Citrate Obtains South Korean Registration Certificate
Zhejiang East Asia Pharmaceutical Subsidiary Gets European CEP Certificate for Antibacterial Drug API Method
Express News | Zhejiang East-Asia Pharmaceutical: Wholly-owned subsidiary cefaclor active pharmaceutical ingredient (enzyme method) has obtained the europe CEP certificate.
East Asia Pharmaceutical: East Asia Pharmaceutical Third Quarter Report 2024
